Group items tagged

The Company Chemist Association (CCA) highlighted its concerns around the recruitment of pharmacists into Primary Care Networks as well as the need for additional investment. Commenting on the Ipsos survey findings, the Malcolm Harrison, the Chief executive of the CCA said: "We welcome the findings of the Ipsos survey, confirming that patients value the quality of service and advice community pharmacies routinely provide. "We are very concerned however that this cancer detection pilot, and all other pharmacy services, are at risk if the NHS is not prepared to inject urgently needed funding into the sector." He stated that without substantial investment, "we will see the continued erosion of the service pharmacies can provide." In addition to the need for critical additional funding the association is also calling on the NHS to pause the recruitment of pharmacists into GP surgeries. He said: "Patients are suffering because the demand for pharmacists in England is now significantly greater than that which the existing workforce can deliver."

Shadow Health Secretary Wes Streeting outlined his plans for NHS reform on Friday (21 April), where he also mentioned a desire to see pharmacies take on more workload and pharmacists' clinical skills to be better utilised. In his speech, he also expressed concern at warnings from the pharmacy sector and pharmacy closures. The Company Chemists' Association (CCA) appreciated Shadow Health Secretary's desire to enhance pharmacies' role in primary care reform but also stated that the sector is in urgently needs a funding injection. Dr. Nick Thayer, Head of Policy at the Company Chemists' Association (CCA) comment: "We are pleased to see the Shadow Health Secretary recognise the enhanced role that pharmacies should play in primary care reform. Mr Streeting wants to see care brought closer to people's homes and more front doors into the NHS. With 89.2% of the population located within a 20-minute walk of a pharmacy, pharmacies do just that. They are essential to realising his vision of a 'neighbourhood health service'. Pharmacies could free up over 42m GP appointments annually, including 10m vaccination appointments. Urgent same-day appointments for minor conditions in pharmacies will immediately benefit patients by increasing GP access. The first step is for the Government to immediately commission a fully-funded Pharmacy First service in England.

Hospitals and healthcare providers across the UK have been notified about the shortage of an anti-inflammatory medicine caused by a manufacturing failure. The Department of Health and Social Care (DHSC) on Friday (3 May) issued a National Patient Safety Alert stating that Erelzi 50mg solution for injection in pre-filled pen will be out of stock from early May until mid-July 2024. "The supply issues have been caused by a manufacturing failure resulting in delays in production and the implementation of global allocations," it said. However, it noted that homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to supply existing patients until mid/late May 2024. Although Erelzi 50mg pre-filled syringes (PFS) are still available, they cannot support a full increase in demand, the DHSC warned.

In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two groundbreaking formulations of cabotegravir. Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1 infection in adults and adolescents weighing at least 35kg at increased risk. This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or PrEP treatments. HIV, a virus notorious for compromising the immune system, has long been a global health concern. Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus's ability to spread.

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio. Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases. Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen. The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas. Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise. Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen, providing a vital treatment option for patients.

The National Health Services England (NHSE) is poised to revolutionise diabetes management with the introduction of the 'artificial pancreas', also known as the Hybrid Closed Loop system, to treat type 1 diabetes. This pioneering initiative, endorsed by the National Institute of Health Care and Excellence (NICE), represents a global first in healthcare innovation. With 269,095 individuals grappling with type 1 diabetes in England, the Hybrid Closed Loop system is set to cater to tens of thousands of children and adults across the nation. This cutting-edge device operates by seamlessly monitoring blood glucose levels and autonomously adjusting insulin dosage through a pump, by eliminating the need for regular insulin injections. Furthermore, it holds the promise of averting life-threatening hypoglycaemic and hyperglycaemia episodes, mitigating significant risks associated with the condition. To facilitate the identification of beneficiaries, NHSE has allocated a substantial sum of £2.5 million, ensuring that those who could benefit from this innovative solution receive the necessary support.

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use. It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient." Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions. Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed. Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.

The final report of the Infected Blood Inquiry has been published today, bringing to light a devastating chapter in the history of the UK's healthcare system. The inquiry, which was launched by former Prime Minister Theresa May in 2017, examined how contaminated blood products infected over 30,000 NHS patients with deadly viruses, including HIV and Hepatitis C, between the 1970s and 1990s. Following the publication of the report, Prime Minister Rishi Sunak issued a formal apology on behalf of successive governments, acknowledging the state's significant failings. He stated that he finds it "impossible to comprehend" how victims felt when injected with deadly diseases through no fault of their own.

The Green Party has previewed its upcoming manifesto with a bold proposal for the National Health Service (NHS) and social care system, promising an unprecedented level of investment to restore and enhance these critical services. By 2030, the Greens aim to inject over £50 billion annually into health and social care, accompanied by an additional £20 billion capital investment to modernise healthcare infrastructure. Green Party Co-Leader Adrian Ramsay emphasised the urgency of these reforms, stating, "Our NHS is at breaking point following 14 years of underfunding." "Patients are stuck in hospital corridors, people can't see their GP or NHS dentist when they need to, and staff are severely overstretched." The manifesto highlights a comprehensive approach to revitalising the NHS, including:

The Pneumococcal Conjugate Vaccine is Known as Killed Vaccine. It uses protein or any other pieces extracted from the bacteria and injected into the immune system to recognize the bacteria.

The Pneumococcal Conjugate Vaccine is Known as Killed Vaccine. It uses protein or any other pieces extracted from the bacteria and injected into the immune system to recognize the bacteria.

The Pneumococcal Conjugate Vaccine is Known as Killed Vaccine. It uses protein or any other pieces extracted from the bacteria and injected into the immune system to recognize the bacteria.

GSK has received approval from FDA for its Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.

SYMPTOMS AFTER EMBRYO TRANSFER Whole of desired action and the enthusiasm of taking injections, going for scans, monitoring your blood test results and approving your embryos are now over. Your doctor has put your embryos .

A surrogate mother is artificially inseminated with donor sperm where the potential father might have had a known defect in the reproductivity leading to a non biological child because a donor has to donate sperms here and this is being injected into the surrogate mother via IUI, IVF or home insemination.

Laser vein removal is a proven, effective treatment for unsightly broken vessels. Leg veins are mainly caused by oestrogen, prolonged standing, obesity and inheritance. Our Cutera NdYAG laser successfully treats leg veins. It is a safe, effective and comfortable procedure , that does not involve painful injections. So to take care of your skin after a laser vein removal treatment follow our aftercare instruction at Lanu Medi Spa Drogheda.

The clinics here also have other formulae for charging the costs. If one clinic charges costlier of egg donor then the other will charge less on this but it will be compensated in some other way. The cost of both ICSI and IVF can be charged together as INR 70000- 100000. Kin majority of Indian clinics,the average price of Intracytoplasmic Sperm Injection is INR 70,000.Additional charges or underlying cost package is meant for Lab Investigation, Scanning charges, Pharmacy, Fifth Day Blastocyst Transfer, Semen Analysis cost at the cost of 600INR.

US-based KYTHERA Biopharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat, which commonly presents as a double chin.

Testosterone heptylate is a long acting; oil based injectable testosterone delivered in France. In real life, heptylate is very much alike to testosterone enanthate, delivering emotional size and quality picks up alongside the standard androgenic symptoms which accompany a testosterone item. Contrasted with enanthate be that as it may, heptylate is marginally shorter acting, albeit not by much.